- Min.Order :10 Milligram
- Purity: ≥98%
- Payment Terms : T/T
Keywords
Oridonin 28957-04-2 standard supplier in China
Quick Details
- Appearance:detailed see specifications
- Application:analysis,activity test,Botanical Reference Materials,Standard materials
- PackAge:According to the clients requirement.
- ProductionCapacity:1|Metric Ton|Day
- Storage:Store at 2~8°C
- Transportation:by air or by ocean shipping
Superiority:
Hubei CuiRan Biotechnology Co., Ltd is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，Traditional Chinese Medicine), Natural Active Pharmaceutical Ingredients worldwide. From small quantities for R&D or reference standard, to large quantities for customizing or manufacturing, Biopurify emphasizes on consistent and reliable services for his customers.
With excellent quality products and good service, we have clients from more than dozens countries and regions, and we pride ourselves in providing our customers with a total satisfaction experiences.
We are doing our best to be your reliable partner for high quality Phytochemicals and Reference Standards from china.
Our main services:
A. Supply active ingredients and reference standards ofTraditional Chinese Medicine, from mgs to kgs scale.
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR, CM and PD services from lab scale, pilot scale to commercial scale(GMP is also available)
E.Traditional Chinese Medicine compounds library
1.Provide traditional Chinese medicine reference materials and natural active ingredients;
2.More than 2200 compounds are available for selection, continuously building high-quality natural product libraries for drug research and development;
3.Provide various screening libraries and more inhibitor products;
4.Provide separation and structural determination of natural products;
5.Laboratory scale pilot to commercial scale collaborative research and process development services.More than 180 experiences in phytochemistry (still increasing)
Each product has passed very strict testing (NMR/MS/HPLC)
Agents from many countries
General tips：For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging：1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition：Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.
Details:
Chemical Properties of Oridonin
| Cas No. | 28957-04-2 | SDF | |
| PubChem ID | 5321010 | Appearance | White powder |
| Formula | C20H28O6 | M.Wt | 364.43 |
| Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
| Synonyms | Isodonol | ||
| Solubility | DMSO : ≥ 150 mg/mL (411.60 mM) *"≥" means soluble, but saturation unknown. |
||
| Chemical Name | (1S,2S,5S,8R,9S,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one | ||
| SMILES | CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C | ||
| Standard InChIKey | SDHTXBWLVGWJFT-XKCURVIJSA-N | ||
| Standard InChI | InChI=1S/C20H28O6/c1-9-10-4-5-11-18-8-26-20(25,19(11,14(9)22)15(10)23)16(24)13(18)17(2,3)7-6-12(18)21/h10-13,15-16,21,23-25H,1,4-8H2,2-3H3/t10-,11-,12-,13+,15+,16-,18+,19-,20+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Source of Oridonin
1 Rabdosia sp.
Biological Activity of Oridonin
| Description | Oridonin has anticancer activity, might be useful as adjunctive therapy for individuals with lymphoid malignancies, including the lethal disease adult T-cell leukemia.It inhibits tumor growth in glioma by inducing cell cycle arrest and apoptosis, inhibits BxPC-3 cell growth through cell apoptosis. |
| Targets | CDK | PARP | Caspase | mTOR | RAF | ERK | STAT | Bcl-2/Bax | JNK | p38MAPK |
| In vitro |
Anti-leukemia effect of oridonin on T-cell acute lymphoblastic leukemia[Pubmed: 25571712] Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 Nov;45(6):903-7. To investigate the antileukemia effect of Oridonin on T-cell acute lymphoblastic leukemia cell line CEM. Experimental study on anti-pancreatic cancer effect of oridonin.[Pubmed: 25566662] Zhong Yao Cai. 2014 Jul;37(7):1230-3. To investigate the apoptotic effect of Oridonin in human pancreatic cancer cells PANC-1, and to explore the underlying mechanism. |
Protocol of Oridonin
| Kinase Assay |
Oridonin inhibits tumor growth in glioma by inducing cell cycle arrest and apoptosis.[Pubmed: 25553351] Cell Mol Biol (Noisy-le-grand). 2014 Dec 30;60(6):29-36. Glioma is the most common malignant intracranial tumors. Despite newly developed therapies, these treatments mainly target oncogenic signals, and unfortunately, fail to provide enough survival benefit in both human patients and mouse xenograft models, especially the first-generation therapies. Oridonin is purified from the Chinese herb Rabdosia rubescens and considered to exert extensive anti-cancer effects on human tumorigenesis. |
| Cell Research |
Oridonin inhibits BxPC-3 cell growth through cell apoptosis.[Pubmed: 25651847] Acta Biochim Biophys Sin (Shanghai). 2015 Mar;47(3):164-73. Oridonin, an ent-kaurene diterpenoid extracted from the traditional Chinese herb Rabdosia rubescens, has multiple biological and pharmaceutical functions and has been used clinically for many years. While the antitumor function of Oridonin has been corroborated by numerous lines of evidence, its anticancer mechanism has not been well documented. |
Preparing Stock Solutions of Oridonin
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.744 mL | 13.7201 mL | 27.4401 mL | 54.8802 mL | 68.6003 mL |
| 5 mM | 0.5488 mL | 2.744 mL | 5.488 mL | 10.976 mL | 13.7201 mL |
| 10 mM | 0.2744 mL | 1.372 mL | 2.744 mL | 5.488 mL | 6.86 mL |
| 50 mM | 0.0549 mL | 0.2744 mL | 0.5488 mL | 1.0976 mL | 1.372 mL |
| 100 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.5488 mL | 0.686 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
References on Oridonin
[Anti-leukemia effect of oridonin on T-cell acute lymphoblastic leukemia].[Pubmed:25571712]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2014 Nov;45(6):903-7.
OBJECTIVE: To investigate the antileukemia effect of Oridonin on T-cell acute lymphoblastic leukemia cell line CEM. METHODS: Human T-cell acute lymphoblastic leukemia cell line CEM was cultured in vitro. The 50% inhibition concentration (IC50) of Oridonin against CEM cells was examined using modified MTT assay. The cellular morphologic changes were observed using a light microscope. The percent of apoptosis of CEM cells after drug treatment was evaluated by flow cytometric analysis. The active levels of AKT/mTOR, RAF/MEK/ ERK, STAT5 signaling pathways and the expression levels of Bcl-2 and BAX were examined by Western blot. RESULTS: Oridonin inhibited the growth of CEM cells in time- and dose dependent manner and the ICs0 of Oridonin was (7. 37+/- 1. 99) mumol/L after 72 h treatment. The cellular membrane of CEM cells treated with Oridonin became unsharp, some of them disintegrated. Oridonin induced apoptosis in CEM cells and the percent of apoptosis rate after 0, 5, 7.5, 10 mumol/L Oridonin treatment for 24 h were (4. 8+/-2. 11)%, (19.03+/-12.54)% ,(40.27+/- 3.31) / and (57. 23 +/- 6. 69)% respectively. Oridonin inhibited activation of mTOR, P70S6, 4EBP1, RAF. ERK and STAT5 signaling protein, which were constitutively activated in CEM cells, however, Oridonin had no inhibitory effect on AKT kinase. Oridonin down-regulated the level of anti apoptotic protein Bcl-2 and up-regulated the expression of pro-apoptotic protein Bax. CONCLUSION: Oridonin exerted antileukemia effect in CEM cells by inhibiting the activation of mTOR/P70/4EBP1, RAF/ERK and STATS signaling pathways, down-regulating the expression of Bel-2 and up-regulating the expression of BAX.
Oridonin inhibits BxPC-3 cell growth through cell apoptosis.[Pubmed:25651847]
Acta Biochim Biophys Sin (Shanghai). 2015 Mar;47(3):164-73.
Oridonin, an ent-kaurene diterpenoid extracted from the traditional Chinese herb Rabdosia rubescens, has multiple biological and pharmaceutical functions and has been used clinically for many years. While the antitumor function of Oridonin has been corroborated by numerous lines of evidence, its anticancer mechanism has not been well documented. In this study, the pancreatic cancer cell line BxPC-3 was used as a model to investigate a possible anticancer mechanism of Oridonin through examining its effects on cell viability. The results showed that Oridonin affected cell viability in a time- and dose-dependent manner. After exposure to different Oridonin concentrations, growth rates and cell cycle arrest of BxPC-3 cells were significantly reduced compared with untreated cells, suggesting its effects on proliferation inhibition. Detailed signaling pathway analysis by western blot analysis revealed that low-dose Oridonin treatment inhibited BxPC-3 cell proliferation by up-regulating p53 and down-regulating cyclin-dependent kinase 1 (CDK1), which led to cell cycle arrest in the G2/M phase. A high-dose Oridonin not only arrested BxPC-3 cells in the G2/M phase but also induced cell accumulation in the S phase, presumably through gammaH2AX up-regulation and DNA damage. In addition, our results showed that a cell subpopulation was stained with propidium iodide after Oridonin treatment. Protein quantification showed that cleaved poly(ADP-ribose) polymerase (PARP) expression was increased after a high-dose Oridonin treatment, especially after long-term exposure. Accompanied by the increased level of deactivated PARP in BxPC-3 cells, the apoptosis initiators caspase-3 and caspase-7 expressions were also significantly increased, suggesting that caspase-mediated apoptosis contributed to cell death.
Oridonin inhibits tumor growth in glioma by inducing cell cycle arrest and apoptosis.[Pubmed:25553351]
Cell Mol Biol (Noisy-le-grand). 2014 Dec 30;60(6):29-36.
Glioma is the most common malignant intracranial tumors. Despite newly developed therapies, these treatments mainly target oncogenic signals, and unfortunately, fail to provide enough survival benefit in both human patients and mouse xenograft models, especially the first-generation therapies. Oridonin is purified from the Chinese herb Rabdosia rubescens and considered to exert extensive anti-cancer effects on human tumorigenesis. In this study, we systemically investigated the role of Oridonin in tumor growth and the underlying mechanisms in human glioma. We found that Oridonin inhibited cell proliferations in a dose- and time-dependent manner in both glioma U87 and U251 cells. Moreover, these anti-cancer effects were also confirmed in a mouse model bearing glioma. Furthermore, cell cycle arrest in S phase was observed in Oridonin-mediated growth inhibition by flow cytometry. Cell cycle arrest in S phase led to eventual cell apoptosis, as revealed by Hoechst 33342 staining and annexin V/PI double-staining. The cell apoptosis might be accomplished through a mitochondrial manner. In all, we were the first to our knowledge to report that Oridonin could exert anti-cancer effects on tumor growth in human glioma by inducing cell cycle arrest and eventual cell apoptosis. The identification of Oridonin as a critical mediator of glioma growth may potentiate Oridonin as a novel therapeutic strategies in glioma treatments.
[Experimental study on anti-pancreatic cancer effect of oridonin].[Pubmed:25566662]
Zhong Yao Cai. 2014 Jul;37(7):1230-3.
OBJECTIVE: To investigate the apoptotic effect of Oridonin in human pancreatic cancer cells PANC-1, and to explore the underlying mechanism. METHODS: MTT assay was used to measure the cell viability. Apoptosis was determined by confocal laser scanning microscope after Hoechst 33342 staining and flow cytometry analysis after PI staining. The regulation of JNK and p38 MAPK signaling pathway proteins was examined by Western blot analysis. RESULTS: Treatment with Oridonin for 24 h resulted in a marked decrease in cell viability in a dose-dependent manner. The IC50 value was determined as 49.80 mumol/L for 24 h. After treatment with 50 micromol/L and 80 mumol/L Oridonin for 24 h, typical apoptotic nucleus alterations were observed with confocal laser scanning microscope and apoptotic rates of PANC-1 cells increased by flow cytometry analysis. Treatment with 80 mumol/L Oridonin down-regulated protein expression of JNK, p38 and increased the expression of p-JNK, p-p38. Furthermore, 80 mumol/L Oridonin treatment decreased the expression of down-stream proteins Caspase-9, Caspase-3 and PARP in the apoptotic pathway as well as activated the cleavage of Caspase-9. CONCLUSION: Oridonin can induce apoptosis of PANC-1 cells through JNK and p38 MAPK pathway proteins.
Description
Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.
You Might Also Like
Related Searches
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View